Day-to-day activities are conducted by its three founders, David Kravitz, Steven Mayer, MD, and Stephen Drake, PhD.
The team has extensive executive management and business development experience in the development, clinical testing, and global commercialization of medical therapeutic and diagnostic products, including in the field of HIV.
Mr. Kravitz is an entrepreneur and inventor who has served in various senior executive, directorship and advisory positions throughout his career in the Life Sciences. For over 20 years, his focus has been in the fields of trauma and transplantation medicine, women’s reproductive health, therapeutics adherence, and regenerative medicine. He is an inventor of several dozen medical technology related patents and has been a founder of med tech companies including Organ Recovery Systems where he served as Chairman and CEO. In 2004, he was named to Fast Company magazine’s “Fast 50” list of North American entrepreneurs. He presently serves as CEO of Lifeline Scientific, Inc., a company that he co-founded. Mr. Kravitz has extensive background in mergers and acquisitions, has led companies through international public and private institutional financings, and the development, regulatory approvals, and launches of several global medical technologies, including the market leading LifePort family of solid organ recovery and transport systems. LifePort is a standard of care in clinical transplantation and has been prominently recognized for its industrial design and engineering.
Acknowledgements include design excellence awards from the medical device industry (MDDA Gold Medal), exhibition at the Smithsonian Cooper-Hewitt National Design Museum, and selection into the permanent Collection of The Museum of Modern Art (MoMA) in New York City. Mr Kravitz’s medical technology developments in transplantation have been widely studied and published in leading peer reviewed scientific journals including the New England Journal of Medicine. Prior to serving in the Life Sciences, his career included advisory and executive roles with companies in the oil and gas and industrial water purification industries. Throughout his career he has remained active in early childhood education, having founded a Montessori based pre-school, literacy curriculum developer, and publisher of books and products in the field of early childhood literacy. Mr Kravitz’s present board affiliations include IDT, Cell and Tissue Systems, and Lifeline Scientific.
Dr. Steven L. Mayer, MD
Chief Medical Officer, Director
Dr. Mayer has over twenty-five years of diverse experience in the diagnostic, device and pharmaceutical industries; he has a Medical Doctor (MD) and a BS degree with honors in Chemical Engineering, both from University of Wisconsin-Madison, USA. He presently serves Non-Executive Director at Lifeline Scientific, Inc. and as Chief Medical Officer at GlucoSentient, Inc. While Dr. Mayer was with Abbott Labs he held several positions including a Medical Director in the Pharmaceutical Division Epidemiology and Outcomes Research where he worked on pharmaco-economic and quality of life assessments of pharmaceutical products. Dr. Mayer has more than 10 years experience with adherence research in many therapeutic areas including HIV/AIDS, psychiatry, antibiotic, endocrine, transplant and cardiovascular. Dr. Mayer was also a member of Abbott’s Anti-Viral Venture team that completed Phase 2 and 3 FDA approval clinical trials and successfully launched Abbott’s HIV Protease Inhibitor Kaletra.
Dr. Mayer has remained active in HIV research and has been co-chair of the International Conference on HIV Treatment Adherence sponsored by IAPAC (International Association of Physicians in AIDS Care) and the NIMH. Earlier Dr. Mayer was a Senior Scientist in Abbott Diagnostic Division Research and Development and a program manager of several diagnostic research projects for new instrument and disposable designs, including successfully developing self-performing immunoassay tests (pregnancy and HIV) for the consumer market. Dr. Mayer invented and designed QwikWash, a commercially successful enzyme immunoassay bead washing system for Abbott Laboratories used to perform millions of HIV and other blood tests on high volume automated hospital and blood bank immunoassay analyzers. Dr. Mayer also served as a Senior Strategic Planner at Abbott Laboratories.
Dr. Drake has a Ph.D. in Finance from the Univ of Washington, Int., Masters in Tax from the Univ of Arizona, BS Accounting and Finance from the Univ of Arizona and is a College of Financial Planning graduate.
Dr. Drake has practiced in the professional consulting corporate community for about 40 years which included the international consulting firm of Andersen Consulting, and a number of large regional consulting firms. He lectures worldwide on a host of business topics.
Dr. Drake serves or has served on multiple corporate Boards of Directors in both the profit and nonprofit areas including pharmaceutical firms, supporting organizations, life science corporations, agricultural, oil and gas and chemical companies.
He has written more than 50 professional articles on tax and financial planning and has approximately 40 years of diversified, professional experience. He travels thoughout the US and abroad lecturing and providing advice for individuals, other professionals and corporations.
Dr. Drake has managed numerous companies over the years and is the long time Chairman of the Board of the Company.
Patent Counsel : Oliff & Berridge, Attorneys at Law
General Counsel : Jennings Strouss, Attorneys at Law